CC BY-NC-ND 4.0 · Laryngorhinootologie 2018; 97(S 02): S106
DOI: 10.1055/s-0038-1640079
Abstracts
Onkologie: Oncology

Antibodies to tumor-associated antigens in head and neck squamous cell carcinoma patients differ by HPV-status

S Laban
1   Universitätsklinik Ulm, Klinik f. HNO & Kopf-Hals-Chirurgie, Ulm
,
D Gangkofner
1   Universitätsklinik Ulm, Klinik f. HNO & Kopf-Hals-Chirurgie, Ulm
,
L Schroeder
2   DKFZ, Abteilung Molekulare Diagnostik onkogener Infektionen (F020), Heidelberg
,
SB Eichmüller
3   DKFZ, GMP & T Cell Therapy Unit (G182), Heidelberg
,
M Broglie Däppen
4   Kantonsspital St. Gallen, Klinik für Hals-Nasen-Ohrenheilkunde und Kopf- Halschi, St. Gallen, Schweiz
,
G Dyckhoff
5   Universitätsklinik Heidelberg, Klinik für Hals-Nasen-Ohrenheilkunde und Kopf- Ha, Heidelberg
,
P Boscolo-Rizzo
6   Universitätsklinik Padua, Abteilung für Neurowissenschaften, Hals-Nasen-Ohrenhei, Treviso, Italien
,
G Wichmann
7   Universitätsklinik Leipzig, Klinik für Hals-Nasen-Ohrenheilkunde und Kopf- Halsc, Leipzig
,
M Pawlita
2   DKFZ, Abteilung Molekulare Diagnostik onkogener Infektionen (F020), Heidelberg
,
D Holzinger
2   DKFZ, Abteilung Molekulare Diagnostik onkogener Infektionen (F020), Heidelberg
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
 
 

    Introduction:

    We have previously established an association of MAGE-/NY-ESO-1 expression and poor prognosis in head and neck squamous cell carcinoma (HNSCC) patients (pt). There is some evidence that TAA differ between HPV-negative (HPV-) and HPV-positive (HPV+) patients. Antibodies (AB) to tumor-associated antigens (TAA) may help to characterize the TAA repertoire in the tumor.

    Methods:

    AB to 29 auto-antigens and HPV-16 E6 were analyzed in serum and plasma samples of 410 HNSCC pt treated at different German cancer centers. As a surrogate marker, reactivity to HPV-16 E6 was used to define the HPV status. Statistical comparison of AB prevalence by HPV-status was performed using a Chi2 test corrected for multiple testing using the method of Benjamini, Krieger and Yekutieli with a false discovery rate of 10%.

    Results:

    Among 410 pt, 126 (31%) were reactive to HPV-16 E6. The five most frequent AB were directed against HPV-16 E6 (31%), MAGE-A3 (13%), SpanXa1 (12%), MAGE-A4 (11%) and MAGE-A1 (10%). In HPV-negative pt, AB against MAGE-A3, MAGE-A4, SpanXa1, LAGE-1a and NY-ESO-1 were detected in ≥10% of pt, whereas in HPV-positive pt AB against SpanXa1, CT-47 and MAGE-A1 were found in ≥10% of pt. Significant differences with regard to the prevalence of AB by HPV-status were detected for p53, MAGE-A3, -A4, -A9, LAGE-1a and NY-ESO-1 (p < 0.022).

    Conclusions:

    The prevalence of antigen-specific AB to TAA differed significantly by HPV-status. In the development of antigen-specific immunotherapy such as cancer vaccines, HPV status has to be acknowledged. Data analysis is ongoing.


    #

    No conflict of interest has been declared by the author(s).

    Dr. med. Simon Laban
    Universitätsklinik Ulm, Klinik f. HNO & Kopf-Hals-Chirurgie,
    Frauensteige 12, 89070,
    Ulm

    Publikationsverlauf

    Publikationsdatum:
    18. April 2018 (online)

    © 2018. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag KG
    Stuttgart · New York